Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 23 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal · 4% above its 52-week low
| 2.24 | 52-week high | +167.46% |
| 2.07 | Previous month high | +147.49% |
| 1.45 | Previous week high | +73.36% |
| 1.25 | Previous month low | +49.45% |
| 1.22 | Previous week low | +45.86% |
| 0.9713 | R3 (classic) | +16.13% |
| 0.9307 | R2 (classic) | +11.27% |
| 0.8900 | Previous day high | +6.41% |
| 0.8833 | R1 (classic) | +5.61% |
| 0.8427 | Pivot | +0.75% |
| 0.8364 | Price now | |
| 0.8020 | Previous day low | −4.11% |
| 0.8010 | 52-week low | −4.23% |
| 0.7953 | S1 (classic) | −4.91% |
| 0.7547 | S2 (classic) | −9.77% |
| 0.7073 | S3 (classic) | −15.43% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.1M | 0.00% | 1.46M | +11% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BMEA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.7 | 22.3 | 11.7 | -11.1 | 1.5 | 6.5 | -20.4 | 43.6 | -20.8 | -37.1 | −32.5% | ||
| 2025 | 7.7 | -30.9 | -26.3 | -1.4 | -31.4 | 25.0 | -7.8 | 17.5 | 3.6 | -32.7 | -19.9 | 13.8 | −68.0% |
| 2024 | 24.5 | -3.2 | -14.6 | -28.2 | -2.0 | -57.2 | 23.8 | 31.6 | 37.8 | -7.2 | -22.7 | -46.4 | −73.3% |
| 2023 | 12.9 | 34.9 | 141.5 | -5.0 | 15.2 | -35.4 | 1.4 | -24.2 | -18.4 | -25.7 | 47.5 | -3.6 | +72.2% |
| 2022 | -3.9 | -10.5 | -30.4 | -32.7 | 83.0 | 118.2 | -11.5 | 8.5 | -15.0 | 12.5 | -34.6 | 17.2 | +13.2% |
| 2021 | 2.1 | -9.8 | -15.5 | 5.8 | -14.2 | -10.3 | 12.4 | -38.3 | −56.0% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Erdtmann Rainer MPresident | Stock Gift at price 0.00 per share. | 150.6K | — |
| Dec 10, 2025 | Erdtmann Rainer MPresident | Purchase at price 1.43 per share. | 30K | $43.00K |
| Dec 1, 2025 | Hitchcock Michael J.M.Chief Executive Officer | Purchase at price 0.99 per share. | 100K | $99.18K |
| Nov 30, 2025 | Erdtmann Rainer MPresident | Purchase at price 1.05 - 1.10 per share. | 50K | $54.55K |
| Jan 30, 2025 | Erdtmann Rainer MPresident | Stock Gift at price 0.00 per share. | 70K | — |
| Nov 28, 2024 | Valle FrancoChief Financial Officer | Stock Award(Grant) at price 6.15 per share. | 495 | $3.05K |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Buy / hold / sell counts